Gebro Pharma launches Kentera, the first transdermal patch for the treatment of overactive bladder

Gebro Pharma has launched Kentera® in Spain, the only oxybutynin transdermal patch to treat incontinence and other symptoms in adult patients with overactive bladder.
Specifically, Kentera® is indicated for the symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency in adult patients with an overactive bladder.
As explained by the head of the Urology Service at the Hospital Nacional de Parapléjicos in Toledo and member of the directors’ board of the Spanish Urology Association, Dr. Manuel Esteban, “The application of oxybutynin in a transdermal patch is easy and it contributes to preventing the uncomfortable side effects of oral anticholinergic treatments, and in addition it offers the advantage of being an administration route that is known and easy for patients because it’s used in other pathologies like pain or menopause.
Kentera® 3.9mg/24 hours the is only formulation of transdermal oxybutynin release, a molecule that’s been considered the gold standard treatment for over 30 years, and which is applied twice a week.
The innovative technology of the Kentera® patch allows the modification of the drug’s pharmacokinetics offering significant advantages in comparison to oral oxybutynin since it reduces the rate of anticholinergic side effects, especially mouth dryness, whilst preserving the high effectiveness of the original molecule.
“The obvious lower rate of side effects and the comfortable administration of the transdermal patch improve the therapeutic compliance and the adherence to a very effective treatment which in its oral formulation is usually abandoned by a large number of patients with the subsequent negative impact on their quality of life, the productivity of their work and their sexual sphere”, describes Urology specialist at the Hospital Universitario in Burgos, Dr. José M. Adot.

Gebro Pharma presents in Spain this innovative treatment option which doesn’t only offer good results in terms of effectiveness and safety but also, unlike the rest of available anticholinergic treatments, Kentera® is administered only twice a week, which is an important advantage in comparison to the daily treatments that are currently commercialized.

Overactive Bladder Syndrome (OAB) in Spain
Overactive bladder syndrome is usually characterized by the presence of involuntary contractions of the detrusor muscle during the bladder filling phase. Its clinical presentation consists of urge urinary incontinence, usually frequent, and nocturia.
The prevalence of OAB in Spain is 11.9% within the adult population, 10.8% of them men and 12.8% women. In the group of over 40s the prevalence increases significantly up to 24.5% of the population, with 17.4% of those affected being men and 25.6% women.